Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GHDX's Cash to Debt is ranked higher than
98% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.74 vs. GHDX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GHDX' s 10-Year Cash to Debt Range
Min: 4.9  Med: 1105.30 Max: No Debt
Current: No Debt
Equity to Asset 0.78
GHDX's Equity to Asset is ranked higher than
76% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. GHDX: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
GHDX' s 10-Year Equity to Asset Range
Min: -3.56  Med: 0.80 Max: 0.89
Current: 0.78
-3.56
0.89
Interest Coverage No Debt
GHDX's Interest Coverage is ranked higher than
97% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. GHDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GHDX' s 10-Year Interest Coverage Range
Min: 80.08  Med: 10000.00 Max: 9999.99
Current: No Debt
80.08
9999.99
F-Score: 2
Z-Score: 12.11
M-Score: -3.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -11.23
GHDX's Operating margin (%) is ranked lower than
57% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. GHDX: -11.23 )
Ranked among companies with meaningful Operating margin (%) only.
GHDX' s 10-Year Operating margin (%) Range
Min: -12348  Med: -12.21 Max: 4.01
Current: -11.23
-12348
4.01
Net-margin (%) -9.62
GHDX's Net-margin (%) is ranked lower than
56% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.51 vs. GHDX: -9.62 )
Ranked among companies with meaningful Net-margin (%) only.
GHDX' s 10-Year Net-margin (%) Range
Min: -12200  Med: -11.74 Max: 3.81
Current: -9.62
-12200
3.81
ROE (%) -18.27
GHDX's ROE (%) is ranked lower than
63% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. GHDX: -18.27 )
Ranked among companies with meaningful ROE (%) only.
GHDX' s 10-Year ROE (%) Range
Min: -1865.06  Med: -16.93 Max: 7.79
Current: -18.27
-1865.06
7.79
ROA (%) -14.50
GHDX's ROA (%) is ranked lower than
63% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. GHDX: -14.50 )
Ranked among companies with meaningful ROA (%) only.
GHDX' s 10-Year ROA (%) Range
Min: -91.5  Med: -18.43 Max: 6.18
Current: -14.5
-91.5
6.18
ROC (Joel Greenblatt) (%) -115.66
GHDX's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. GHDX: -115.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GHDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2388.09  Med: -83.66 Max: 74.51
Current: -115.66
-2388.09
74.51
Revenue Growth (3Y)(%) 9.40
GHDX's Revenue Growth (3Y)(%) is ranked higher than
68% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. GHDX: 9.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GHDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 19.70 Max: 136.8
Current: 9.4
0
136.8
» GHDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GHDX Guru Trades in Q2 2014

Chuck Royce 33,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

GHDX Guru Trades in Q3 2014

Chuck Royce 33,000 sh (unchged)
» More
Q4 2014

GHDX Guru Trades in Q4 2014

Jim Simons 12,200 sh (New)
Chuck Royce 33,000 sh (unchged)
» More
Q1 2015

GHDX Guru Trades in Q1 2015

Jim Simons 36,900 sh (+202.46%)
Chuck Royce 33,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GHDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.70
GHDX's P/B is ranked lower than
70% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. GHDX: 5.70 )
Ranked among companies with meaningful P/B only.
GHDX' s 10-Year P/B Range
Min: 3.3  Med: 7.26 Max: 14.23
Current: 5.7
3.3
14.23
P/S 3.17
GHDX's P/S is ranked lower than
51% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. GHDX: 3.17 )
Ranked among companies with meaningful P/S only.
GHDX' s 10-Year P/S Range
Min: 2.17  Med: 4.25 Max: 20.45
Current: 3.17
2.17
20.45
Current Ratio 4.11
GHDX's Current Ratio is ranked higher than
67% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. GHDX: 4.11 )
Ranked among companies with meaningful Current Ratio only.
GHDX' s 10-Year Current Ratio Range
Min: 3.54  Med: 4.75 Max: 15.83
Current: 4.11
3.54
15.83
Quick Ratio 4.11
GHDX's Quick Ratio is ranked higher than
71% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. GHDX: 4.11 )
Ranked among companies with meaningful Quick Ratio only.
GHDX' s 10-Year Quick Ratio Range
Min: 3.54  Med: 4.75 Max: 15.83
Current: 4.11
3.54
15.83
Days Sales Outstanding 46.12
GHDX's Days Sales Outstanding is ranked higher than
75% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. GHDX: 46.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
GHDX' s 10-Year Days Sales Outstanding Range
Min: 22.03  Med: 29.32 Max: 83.72
Current: 46.12
22.03
83.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.71
GHDX's Price/Net Cash is ranked higher than
51% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.55 vs. GHDX: 10.71 )
Ranked among companies with meaningful Price/Net Cash only.
GHDX' s 10-Year Price/Net Cash Range
Min: 3.64  Med: 12.16 Max: 22.82
Current: 10.71
3.64
22.82
Price/Net Current Asset Value 6.83
GHDX's Price/Net Current Asset Value is ranked higher than
55% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.07 vs. GHDX: 6.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GHDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.53  Med: 8.52 Max: 17
Current: 6.83
3.53
17
Price/Tangible Book 5.65
GHDX's Price/Tangible Book is ranked lower than
55% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.96 vs. GHDX: 5.65 )
Ranked among companies with meaningful Price/Tangible Book only.
GHDX' s 10-Year Price/Tangible Book Range
Min: 3.3  Med: 7.16 Max: 11.72
Current: 5.65
3.3
11.72
Price/Projected FCF 4.78
GHDX's Price/Projected FCF is ranked lower than
79% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.98 vs. GHDX: 4.78 )
Ranked among companies with meaningful Price/Projected FCF only.
GHDX' s 10-Year Price/Projected FCF Range
Min: 4.17  Med: 5.26 Max: 38.47
Current: 4.78
4.17
38.47
Price/Median PS Value 0.74
GHDX's Price/Median PS Value is ranked higher than
78% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. GHDX: 0.74 )
Ranked among companies with meaningful Price/Median PS Value only.
GHDX' s 10-Year Price/Median PS Value Range
Min: 0.53  Med: 1.00 Max: 3.71
Current: 0.74
0.53
3.71
Earnings Yield (Greenblatt) (%) -4.10
GHDX's Earnings Yield (Greenblatt) (%) is ranked lower than
62% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.50 vs. GHDX: -4.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GHDX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -4.13  Med: 0.90 Max: 1.3
Current: -4.1
-4.13
1.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:G7H.Germany,
Genomic Health Inc was incorporated in Delaware in August 2000. It is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company is engaged in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The Company's Oncotype DX breast and colon tests have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company provides its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ, or DCIS and a Genomic Prostate Score, or GPS, for prostate cancer. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, or RT-PCR, in standard tumor pathology specimens to provide tumor-specific information, or the "oncotype" of a tumor. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and its Oncotype DX colon cancer test analyzes the expression levels of 12 genes. Its Oncotype DX prostate cancer test measures the level of expression of 17 genes across four biological pathways to predict prostate cancer aggressiveness in men with low risk disease. It has a direct commercial presence with employees and consultants in the United States and certain other countries, and its Oncotype DX breast and colon cancer tests are also available outside of the United States through a network of distributors. The Company faces competition from companies that offer products or have conducted research to profile genes, gene expression or protein expression in breast, colon or prostate cancer, including public companies such as, GE Healthcare, a business unit of General Electric Company, Hologic, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Novartis AG, Qiagen N.V. and Response Genetics, Inc., and many private companies. It faces competition from commercial laboratories with distribution networks for diagnostic tests, such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated. The Company holds 32 issued patents in the United States and 65 issued patents outside of the United States. As a clinical reference laboratory, the Company is subject to hold certain federal, state and local licenses, certifications and permits to conduct its business.
» More Articles for GHDX

Headlines

Articles On GuruFocus.com
CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 

More From Other Websites
Genomic's Oncotype DCIS Score Betters Treatment Guidance - Analyst Blog Jun 25 2015
Healthcare-Focused Fund Camber Capital’s Top Picks: Masimo Corporation (MASI), The Medicines... Jun 23 2015
Journal of Surgical Oncology Publishes Study Showing Oncotype DX® DCIS Score™ Result Changes... Jun 23 2015
Journal of Surgical Oncology Publishes Study Showing Oncotype DX® DCIS Score™ Result Changes... Jun 23 2015
GENOMIC HEALTH INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 17 2015
Genomic Health Liquid Biopsy Test Fit for Bladder Cancer - Analyst Blog Jun 17 2015
Genomic Health Presents Positive Proof-of-Concept Data for Bladder Cancer Liquid Biopsy Test Jun 16 2015
Genomic Health Presents Positive Proof-of-Concept Data for Bladder Cancer Liquid Biopsy Test Jun 16 2015
Edited Transcript of GHDX earnings conference call or presentation 5-May-15 8:30pm GMT Jun 12 2015
Genomic Health to Present Proof-of-Concept Bladder Cancer Liquid Biopsy Data at AACR Precision... Jun 11 2015
Genomic Health to Present Proof-of-Concept Bladder Cancer Liquid Biopsy Data at AACR Precision... Jun 11 2015
Oncotype DX® Presentations at ASCO in Breast and Prostate Cancer Reinforce Genomic Health's... Jun 01 2015
Oncotype DX® Presentations at ASCO in Breast and Prostate Cancer Reinforce Genomic Health's... Jun 01 2015
Genomic's Prostate Cancer Test Recommended by Palmetto - Analyst Blog May 27 2015
Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference May 27 2015
Multiple Oncotype DX® Presentations at the American Society of Clinical Oncology Annual Meeting... May 27 2015
Multiple Oncotype DX® Presentations at the American Society of Clinical Oncology Annual Meeting... May 27 2015
Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference May 27 2015
Genomic Health Announces Favorable Draft Local Coverage Determination from Palmetto GBA® on... May 21 2015
Genomic Health Announces Favorable Draft Local Coverage Determination from Palmetto GBA® on... May 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK